Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep;21(9):1339-42.
doi: 10.1128/CVI.00263-14. Epub 2014 Jul 23.

Hepatitis B virus antibody levels 7 to 9 years after booster vaccination in Alaska native persons

James W Keck  1 , Lisa R Bulkow  2 , Gregory A Raczniak  3 , Susan E Negus  4 , Carolyn L Zanis  2 , Michael G Bruce  2 , Philip R Spradling  5 , Eyasu H Teshale  5 , Brian J McMahon  6
Affiliations

Hepatitis B virus antibody levels 7 to 9 years after booster vaccination in Alaska native persons

James W Keck et al. Clin Vaccine Immunol. 2014 Sep.

Abstract

Hepatitis B antibody persistence was assessed in individuals who had previously received a vaccine booster. We measured hepatitis B surface antigen antibody (anti-HBs) levels 7 to 9 years post-hepatitis B booster in individuals with primary vaccination at birth. While 95 (91.3%) of 104 participants had detectable anti-HBs (minimum, 0.1 mIU/ml; maximum, 1,029 mIU/ml), only 43 (41%) had protective levels of ≥10 mIU/ml. Pre- and week 4 postbooster anti-HBs levels were significant predictors of hepatitis B immunity at follow-up (P < 0.001). Almost all participants had detectable anti-HBs 7 to 9 years after the hepatitis B vaccine booster, but less than half had levels ≥10 mIU/ml.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Geometric mean concentrations (GMC) of anti-HBs for the three vaccine groups, AS (adolescent plasma), AR (adolescent recombinant), and CR (child recombinant), and a combined total for each of the time periods evaluated.
See this image and copyright information in PMC

References

    1. Bonanni P, Pesavento G, Bechini A, Tiscione E, Mannelli F, Benucci C, Nostro AL. 2003. Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine 21:685–691. 10.1016/S0264-410X(02)00580-7 - DOI - PubMed
    1. Harpaz R, McMahon BJ, Margolis HS, Shapiro CN, Havron D, Carpenter G, Bulkow LR, Wainwright RB. 2000. Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. J. Infect. Dis. 181:413–418. 10.1086/315259 - DOI - PubMed
    1. Fitzsimons D, Francois G, Hall A, McMahon B, Meheus A, Zanetti A, Duval B, Jilg W, Bocher WO, Lu SN, Akarca U, Lavanchy D, Goldstein S, Banatvala J, Damme PV. 2005. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 23:4158–4166. 10.1016/j.vaccine.2005.03.017 - DOI - PubMed
    1. European Consensus Group on Hepatitis Immunity B. 2000. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 355:561–565. 10.1016/S0140-6736(99)07239-6 - DOI - PubMed
    1. McMahon BJ, Dentinger CM, Bruden D, Zanis C, Peters H, Hurlburt D, Bulkow L, Fiore AE, Bell BP, Hennessy TW. 2009. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J. Infect. Dis. 200:1390–1396. 10.1086/606119 - DOI - PubMed

Substances

LinkOut - more resources